echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The development of classical Chinese medicine prescriptions will become the special focus of new drugs in China

    The development of classical Chinese medicine prescriptions will become the special focus of new drugs in China

    • Last Update: 2017-03-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    During the 13th Five Year Plan period, the new drug project will comprehensively enhance the innovation ability and international competitiveness of GLP platform, make it give full play to the service of new drug R & D innovation chain, and ensure the safety of drug use and the entry of China's innovative drugs into the international echelon (the development of traditional Chinese medicine classic prescription will become the key national new drug special picture source: Baidu picture) On February 22, the Ministry of science and technology organized a national science and technology major special press conference for major new drug creation, with the special key tasks adjusted to major varieties and key technology research and development, core technology innovation platform and capacity-building, including focusing on the development of classic Chinese medicine prescriptions, as well as the Research of traditional Chinese medicine compounds and their active ingredients with distinctive advantages Sang Guowei, chief engineer of new drug technology and academician of Chinese Academy of engineering, said that during the 13th Five Year Plan period, new drug project will comprehensively enhance the innovation ability and international competitiveness of GLP platform of China's drug non clinical research quality management standard certification, make it give full play to the service of innovation chain of new drug research and development, ensure the drug safety and enter the international echelon of China's innovative drugs Next, the key tasks of the major national projects will be adjusted to major varieties and key technology research and development, core technology innovation platform and capacity building Grasp the frontier of international technology development and develop major innovative products with new structure, new target and new mechanism We will promote multidisciplinary collaborative innovation, focus on the development of classic Chinese medicine prescriptions, and Research on traditional Chinese medicine compounds and their active ingredients with distinctive advantages We will accelerate the development of clinically needed varieties, accelerate the research and development process of key varieties (more than 200) in the clinical trial stage, and break through a batch of key technologies such as preparations Fully rely on various technical platforms and national key laboratories that have been built for new drug projects, promote the opening and sharing of resources, and establish a collaborative innovation mechanism of interdisciplinary, in-depth integration of production, learning and research In the eight years since the implementation of the new drug program, the R & D and innovation capacity and industrial development of China's biomedical industry have been continuously enhanced By the end of the 12th Five Year Plan, 90 varieties have obtained new drug certificates and 135 varieties have obtained clinical approval documents The R & D and innovation capacity of new drugs has been internationally recognized, and Di'ao Xinxuekang and Danshen capsule have been approved by the European Union The first prize of national science and technology progress was awarded to five projects, including the construction of modern Chinese medicine new drug discovery and evaluation technology platform A number of bottleneck key technologies, such as bio macromolecular drug delivery and secondary development of Chinese patent medicine, have been broken through According to preliminary statistics, the central government has invested 12.8 billion yuan in new drugs, realizing a direct economic benefit of 160 billion yuan Chen Chuanhong, director of major special office, Qin Huaijin, director of new drug implementation management office and director of science and Education Department of national health and Family Planning Commission, introduced the overall progress of major national science and technology projects.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.